Your browser doesn't support javascript.
loading
Cellular Trafficking of Sn-2 Phosphatidylcholine Prodrugs Studied with Fluorescence Lifetime Imaging and Super-resolution Microscopy.
Maji, Dolonchampa; Lu, Jin; Sarder, Pinaki; Schmieder, Anne H; Cui, Grace; Yang, Xiaoxia; Pan, Dipanjan; Lew, Matthew D; Achilefu, Samuel; Lanza, Gregory M.
Afiliación
  • Maji D; Optical Radiology Lab, Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Lu J; Department of Biomedical Engineering, Washington University in St. Louis, MO 63130, USA.
  • Sarder P; Department of Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA.
  • Schmieder AH; Department of Pathology and Anatomical Sciences, Jacobs School of Medicine & Biomedical Sciences, University of Buffalo, Buffalo, NY 14203.
  • Cui G; Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Yang X; Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Pan D; Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Lew MD; Department of Bioengineering, University of Illinois at Urbana-Champaign, Champaign, IL, USA.
  • Achilefu S; Department of Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA.
  • Lanza GM; Optical Radiology Lab, Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Precis Nanomed ; 1(2): 128-145, 2018 Jul.
Article en En | MEDLINE | ID: mdl-31249994
ABSTRACT
While the in vivo efficacy of Sn-2 phosphatidylcholine prodrugs incorporated into targeted, non-pegylated lipid-encapsulated nanoparticles was demonstrated in prior preclinical studies, the microscopic details of cell prodrug internalization and trafficking events are unknown. Classic fluorescence microscopy, fluorescence lifetime imaging microscopy, and single-molecule super-resolution microscopy were used to investigate the cellular handling of doxorubicin-prodrug and AlexaFluor™-488-prodrug. Sn-2 phosphatidylcholine prodrugs delivered by hemifusion of nanoparticle and cell phospholipid membranes functioned as phosphatidylcholine mimics, circumventing the challenges of endosome sequestration and release. Phosphatidylcholine prodrugs in the outer cell membrane leaflet translocated to the inner membrane leaflet by ATP-dependent and ATP-independent mechanisms and distributed broadly within the cytosolic membranes over the next 12 h. A portion of the phosphatidylcholine prodrug populated vesicle membranes trafficked to the perinuclear Golgi/ER region, where the drug was enzymatically liberated and activated. Native doxorubicin entered the cells, passed rapidly to the nucleus, and bound to dsDNA, whereas DOX was first enzymatically liberated from DOX-prodrug within the cytosol, particularly in the perinuclear region, before binding nuclear dsDNA. Much of DOX-prodrug was initially retained within intracellular membranes. In vitro anti-proliferation effectiveness of the two drug delivery approaches was equivalent at 48 h, suggesting that residual intracellular DOX-prodrug may constitute a slow-release drug reservoir that enhances effectiveness. We have demonstrated that Sn-2 phosphatidylcholine prodrugs function as phosphatidylcholine mimics following reported pathways of phosphatidylcholine distribution and metabolism. Drug complexed to the Sn-2 fatty acid is enzymatically liberated and reactivated over many hours, which may enhance efficacy overtime.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Precis Nanomed Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Precis Nanomed Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
...